Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

Stage II Breast Cancer Clinical Trial

Official title:

Presurgical Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women With Stage I-II Primary Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01800422
• Other study ID #: NU 12B09
• Secondary ID: NCI-2012-03189ST
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: June 2013
• Est. completion date: March 2022

Study information

• Verified date: January 2020
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether or not the medication that blocks the effects of the hormone progesterone (CDB-4124 or Proellex) will decrease the growth rate of breast cancer cells as compared to a placebo. CDB-4124 (also called Proellex) is a medication that works against the hormone, progesterone. The researchers in this study would like to compare changes in breast cancer cells of women who have taken CDB-4124 prior to surgery to those from women who have taken a placebo pill prior to surgery.

Description:

PRIMARY OBJECTIVES:

I. To test the hypothesis that treatment with the selective progesterone receptor modulator (SPRM) CDB-4124 (telapristone acetate) will have an anti-tumor effect in women with early-stage breast cancer, defined as a significant decrease in tumor proliferation (Ki67 labeling index).

SECONDARY OBJECTIVES:

I. Measure changes in apoptosis using IHC (cleaved caspase 3 or TUNEL). II. Measure changes in blood estradiol and progesterone levels. III. Compare the breast tissue concentrations of CDB-4124 and its metabolite (CDB4453) to plasma concentrations at the end of therapy.

IV. Assess adverse events.

TERTIARY OBJECTIVES:

I. Measure protein expression of related targets (including estrogen receptor alpha (ERA), estrogen receptor beta (ERB), progesterone receptor isoforms progesterone receptor alpha [PRA], progesterone receptor beta [PRB], tumor necrosis factor receptor superfamily, member 11a, NFKB activator [RANK], tumor necrosis factor (ligand) superfamily, member 11 [RANKL], and either cyclin-dependent kinase 2 [cdk2] or cyclin-dependent kinase 4 [cdk4],) using IHC at baseline and after treatment.

II. Perform ribonucleic acid (RNA) microarray analysis comparing tumors and normal tissue from the intervention and control groups.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive telapristone acetate orally (PO) once daily (QD) for 2-10 weeks and then undergo surgical resection.

ARM II: Patients receive placebo orally once daily for 2-10 weeks and then undergo surgical resection.

After completion of study treatment, patients are followed up for 1 month.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 50
• Est. completion date: March 2022
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects must be females with a histological diagnosis of invasive breast cancer clinical stage T1-2, N01 and be candidates for primary resection of this cancer; note: subjects with bilateral cancer are eligible

• Primary tumor stage T1-2 at the time of initial diagnosis and ipsilateral nodes must be N0-1 by clinical evaluation. Staging is routinely based on the NCCN Clinical Practice Guidelines and TNM Nomenclature for Breast Cancer from AJCC Cancer Staging Manual. All breast cancer patients routinely undergo axillary ultrasound to evaluate nodal involvement.

• Subjects must have greater than 0.5 cm of IBC on core (5 cores).

• Subjects must be age > or = 18 years.

• Subjects must exhibit an ECOG performance status of 0 or 1.

• Subjects must be able and willing to schedule surgical resection of their tumor 2 or more weeks following the start of the study agent.

• Subjects must have adequate hepatic and renal function, within 6 weeks prior to registration. The liver function tests include total bilirubin (<1.5xULN; Gilbert"s allowed 3x ULN), ALT/ AST (<2.5xULN) and alkaline phosphatase(<2.5xULN); the standard renal function tests include blood urea nitrogen (BUN), and creatinine and must be < 2XULN.

• Subjects of child-bearing potential must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.

• A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; OR

• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

• Subjects of child bearing potential must have a negative urine pregnancy test within 5 days prior to first dose of the study drug.

• Subjects must have the ability to understand and the willingness to sign a written informed consent. Informed consent must be obtained prior to registration on the study

Exclusion Criteria

• Subjects must not have a breast cancer diagnosis of ductal carcinoma in situ only (DCIS)

• Subjects must not have received any other breast cancer-specific therapy prior to registration

• Subjects must not have received any oral contraceptive or postmenopausal hormones within one month prior to their diagnostic biopsy AND must agree not to use exogenous sex hormones while on the study

• Subjects must not have a history of any significant renal or hepatic disease requiring ongoing medical therapy or clinical intervention

• Subjects must not have a history of thromboembolic disorder or cerebral vascular disease

• Subjects must not have a body mass index (BMI) > 39

• Subjects must not be pregnant or nursing

• Subjects must not be receiving any other investigational agents

• Subjects must not have allergies to any compounds similar to CDB-4124

• While participating, subjects must agree not to use soy supplements, over the counter estrogen supplements like Estroven, Chinese herbs, or other over-the-counter (OTC) herbal products

Related Conditions & MeSH terms

• Breast Neoplasms
• Stage IA Breast Cancer
• Stage IB Breast Cancer
• Stage II Breast Cancer

Intervention

Drug:
• telapristone acetate
Given orally

Other:
• placebo
Given orally

Procedure:
• therapeutic conventional surgery
Undergo surgical resection

Other:
• laboratory biomarker analysis
Correlative studies
• questionnaire administration
Ancillary studies

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
Northwestern University	Breast Cancer Research Foundation, Repros Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Measure protein expression of related biomarkers	Measurement of protein expression in related biomarkers will be taken, from biopsy tissue, at baseline and on the day of surgery.	At baseline to time of surgery (between 2-10 weeks, up to 10 weeks)
Other	Perform RNA microarray analysis comparing tumors and normal tissue between patients receiving study drug and patients receiving placebo	RNA microarray analysis will be conducted at baseline and on the day of surgery comparing tumors as well as normal tissue from the patients receiving treatment drug and patients receiving placebo.	Baseline to time of surgery (between 2-10 weeks, up to 10 weeks)
Primary	Measurable decrease in tumor growth from baseline to time of surgery	Treatment efficacy will be assessed by comparing tissue samples from the baseline biopsy and tissue samples collected from the day of surgery to measure if there is a decrease in tumor growth.	Baseline to time of surgery (between 2-10 weeks, up to 10 weeks)
Secondary	Compare changes in expression of apoptosis marker at the time of surgery	Using tissue samples, the expression of apoptosis marker will be measured in the intervention group and compared to the placebo group at the time of surgery.	At time of surgery (between 2-10 weeks, up to 10 weeks)
Secondary	Measure changes in blood estradiol and progesterone levels	Serum estradiol and progesterone levels will be measured at baseline and at the time of surgery to assess any changes.	Baseline to time of surgery (between 2-10 weeks, up to 10 weeks)
Secondary	Compare breast tissue concentrations of study drug and its metabolite (CDB4453) to plasma concentrations at the end of treatment	Breast tissue concentrations of study drug will be measured in tumor and normal tissue adjacent to the tumor at the time of surgery. Plasma concentrations of drug will also be measured for comparison to see if there is a correlation between tissue concentration of drug and the reduction in tumor growth after treatment.	At the time of surgery (between 2-10 weeks, up to 10 weeks)
Secondary	Liver and renal function as well as symptom evaluation (via questionnaire) will be analyzed to assess adverse events experienced	Adverse events will be assessed throughout treatment by evaluating liver and renal function tests that will be performed at baseline, week 4, and at the post-intervention (pre-surgical) visit. Symptom measurements (using a questionnaire) will be performed at baseline, post-intervention (pre-surgical), and 1 month following surgery.	At baseline and every 2 weeks while on treatment, day of surgery (between 2-10 weeks, up to 10 weeks), and 1 month following surgery